AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Mild Traumatic Brain Injury Symptoms9/20/2021 Symptoms of a Mild Traumatic Brain InjuryIf you or your loved one has suffered a mild or severe TBI, the damage can have lasting effects on the victim’s health and well-being. Even mild injury could signal a more serious internal problem, such as bruising or bleeding of the brain. Mild TBI is classified as having a GCS score between 13 and 15. There may be posttraumatic amnesia lasting less than 1 day or not, and a loss of consciousness lasting less than 30 minutes, although there may not be a loss of consciousness.
Symptoms of a mild traumatic brain injury include:
The symptoms of a mild traumatic brain injury may be long-lasting, affecting one’s self-esteem and confidence, which can be nearly as damaging as the cognitive effects. If you were involved in an accident that led to a Traumatic Brain Injury symptoms.
0 Comments
Read More
Back to Blog
Extensive Ulcerative Colitis9/17/2021 Patients with extensive ulcerative colitis are at increased risk of developing complications. Although long-term treatment for ulcerative colitis has proven effective in reducing symptoms and the possibility of relapse, additional therapies are available to treat underlying conditions that may trigger the development of ulcers. These additional therapies are shown to be more effective in the long term than current treatment modalities. This article focuses on one such therapy - ulcerative colitis antibiotics.
Ulcerative colitis antibiotics are used to achieve a two-fold benefit in patients with extensive ulcerative colitis. First, to maintain remission in those with a mild-to-moder inflammatory response or mild-to-moder first presentation of ulcerative colitis or at least minimal dysentery. Second, to prevent the re-occurrence of disease in those with an initial or subsequent chronic inflammatory response. If clinical improvement is noted, the previously prescribed oral aminoglycan or sulfamethoxazole combination is continued in the attempt to maintain remission. If this fails to provide significant improvement, a second course of oral aminoglycan or sulfamethoxazole is added. If both initial and ongoing treatments are unable to control the disease, additional systemic or topical immunomodulators may be recommended in order to maintain remission or prevent the development of opportunistic infections. In most patients with extensive ulcerative colitis who respond favorably to a course of aminoglycan or sulfamethoxazole, eradication of the underlying pathology by surgery or other procedures does not necessarily cure the disease. It is important, however, that even patients who do not respond favorably to these treatments be monitored for the long-term implications of these drugs on their health and the possibility of relapse. Patients with extensive ulcerative colitis who are not experiencing progression or worsening of their symptoms should be monitored for liver function, kidney function and the levels of immunoglobulin detected in the blood. These levels can be reduced in those with extensive ulcerative colitis who are also experiencing low levels of interferon in their blood. Some of the more unusual consequences of extensive ulcerative colitis are liver enlargement or fibrosis, fistula, Crohn's Disease (affecting the intestines), lypokia (frozen shoulder), and polydipsia (difficulties with absorption). Each of these conditions can be potentially life-threatening if untreated. Fistula is a blockage in the inner bowel, which can be extremely dangerous if left untreated, as it can be the starting point of fistula (intestinal bleeding). Fibrosis of the liver can lead to liver failure, polydipsia (difficulties with absorption) and Crohn's Disease (a chronic inflammatory bowel disease) and can also potentially cause pancreatitis. Symptoms of Crohn's Disease include extreme pain and a characteristic fecal form along with abdominal bloating. Sclerotherapy is used as an adjunctive therapy for patients with extensive symptoms of ulcerative colitis and associated with chronic pancreatic disease. It involves the injection of a solution of an anti-sclerosant into the affected area, which prevents the release of exuded fluids. This can reduce the pain, tenderness and discomfort caused by this disease. The use of an Sclerosant also decreases the ability of the immune cells to protect the skin from infection. Sclerotherapy has been shown to improve the overall health of patients with both ulcerative and pancreatic diseases. When the Sclerosant is no longer effective, the doctor may choose to perform a colostomy. In most patients, this surgery will be performed at the end of the third year following diagnosis. Patients who have severe symptoms that cannot be treated with an Sclerosant may be referred for a surgical procedure to remove the inflamed colon and/or lower part of the small intestine. Some physicians choose to treat patients who exhibit either a positive Sclerosant response or clinical remission with an operatively invasive procedure. Patients who are diagnosed with extensive damage may have a high chance to have a colectomy if the severity of their disease is deemed to be so severe that a complete removal of the colon is not enough to alleviate the symptoms. |